| Chief Investigator: |
Professor Daniel Rea
Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Birmingham. B15 2TT
+44 (0)121 414 5345 |
| Sponsor: |
University of Birmingham |
| Funder: |
Biotheranostics Inc. (Diagnostic Testing) |
| Disease Site: |
Breast |
| Trial Type: |
Retrospective sample collection and extended follow-up of the Adjuvant Tamoxifen - To Offer More? (aTTom) trial |
| Status: |
Active |
| UKCRN Study ID (if applicable): |
N/A |
| N/AISRCTN Reference Number: |
N/A |
| Open to New Sites? |
NO |
| Start Date: |
25-Aug-2016 |
| Anticipated End Date: |
01-Aug-2020 |
| CRCTU Trial Management Team: |
B-Team |
| Trial Email Address: |
aTTom-extended@trials.bham.ac.uk |
The aTTom-Extended study based on the previously approved clinical trial aTTom (REC (01)97/34). The Adjuvant Tamoxifen Treatment Offer More (aTTom) Clinical Trial was designed to determine if taking tamoxifen for 10 years compared with the standard 5 years would improve patients’ outcome in patients with breast cancer. Randomisation was completed in 2008. All patients are now on follow up and have completed allocated therapy.
The follow-on aTTom-Extended study proposes to continue the long term follow up of patients enrolled into this study through an application to Health and Social Care Information Centre (HSCIC) for mortality data. Additionally the study involves the retrospective collection of the patients’ primary resection tumour blocks stored at the time of surgery as routine standard care.
Information for Patients Who Took Part in the aTTom Trial
A patient summary and information about how to withdraw your consent for further processing of your data or the collection of tissue samples as part of the aTTom-Extended trial can be found here:
aTTom and aTTom-Extended Patient Summary
For more information please contact the aTTom trial team on attom@trials.bham.ac.uk.